Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This proposed phase II trial will investigate the combination of irinotecan, carboplatin and
bevacizumab along with radiation in the treatment of patients with limited-stage SCLC. This
study differs from our "maintenance" bevacizumab trial in that bevacizumab will begin with
the initial chemotherapy treatment. Irinotecan/platinum regimens are emerging as standard
treatments for patients with extensive-stage disease. Adding a novel minimally toxic agent to
this regimen up front may further enhance this doublet's efficacy without contributing to
toxicity. This trial will be one of the first clinical trials to evaluate a combination of
targeted therapy and chemotherapy in the up front treatment of a common solid tumor.